INTEGRATED DIAGNOSIS OF LUNG CANCER - HOW CAN WE OBTAIN ALL THE USEFUL DIAGNOSTIC INFORMATION WITH A SMALL BIOPSY?
May 18, 2017
Introduced by: Dr Marie Florescu

NEW!
DR. MING-SOUND TSAO, FRCPC, MD

Dr. Tsao is a Consultant Thoracic Pathologist and Senior Scientist at the Princess Margaret Cancer Centre, University Health Network, Professor of Laboratory Medicine and Pathobiology, and the M. Qasim Choksi Chair in Lung Cancer Translational Research at the University of Toronto. Dr. Tsao received his B.Sc. from the Simon Fraser University and M.D. from the University of British Columbia. He trained as an Anatomic Pathologist at McGill University, and as an experimental pathologist at the University of North Carolina School of Medicine at Chapel Hill. He was a past faculty member in the Department of Pathology at McGill University and the Montreal General Hospital, Montreal, Canada.

Dr. Tsao is a member and Past Chair of the IASLC Pathology Committee, a member of the IASLC Staging and Prognostic Factor Committee, and a co-editor of the IASLC Atlas of ALK Testing in Lung Cancer. He was a past Associate Editor of the Journal of Thoracic Oncology and past Editorial Board member of the Journal of Clinical Oncology.

Dr. Tsao is the Chair of the Correlative Science and Tumor Biology Committee of the NCIC Clinical Trials Group. He has published more than 400 peer-reviewed manuscripts. His clinical and translational research interests include prognostic and predictive factors, including gene expression signature and genomic pathology in non-small cell lung cancer, and standardization of molecular testing in lung cancer.

Dr. Tsao was the recipient of the 2015 Mary Matthews Pathology Award from the International Association for the Study of Lung Cancer (IASLC), and the 2011 O. Harold Warwick Award from the Canadian Cancer Society.

Title:

INTEGRATED DIAGNOSIS OF LUNG CANCER - HOW CAN WE OBTAIN ALL THE USEFUL DIAGNOSTIC INFORMATION WITH A SMALL BIOPSY?

Description

  • To understand the importance of molecular testing in the diagnosis and management of NSCLC
  • To be familiarized with new technologies that allow for more comprehensive molecular diagnoses
  • To appreciate how quantity of tissue impacts the molecular testing that can be done, and the trade-offs with minimizing procedural risks to patients
  • To discuss ways that ensure maximal diagnostic value is obtained when limited tissue is available

Keywords

molecular testing, diagnosis and management of NSCLC new technologies, minimizing procedural risks to patients, discuss ways that ensure maximal diagnostic value

Category(ies)

Visiting Speakers Program in Oncology (VSPO); Oncology/Oncologie;

Accredited/Certified (1)
You must login to view this conference
 
REGISTER NOW As New User
ACCESS As Returning User

 

From Montreal, QC, Canada
Copyright © 2002-2017 Continuing Professional Development (CPD) Office,
Faculty of Medicine, McGill University